Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-13 (deraktionaer.de)
The deepest stood since 2013! Biogen share rushes into the basement - the shareholder
Disappointing numbers have been pressing the biogen's biogenic stock for more than one decade. Above all, the multiple sclerosis business and the proceeds with the medication of Skyclary's, which the company incorporated through the takeover of Reata, remained behind the expectations of the market. There is also a weak view.
Read more
2025-01-27 (biospace.com)
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal -
Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders
Read more
2025-01-10 (stocktitan.net)
Sage Therapeutics Receives Surprise $7.22 Per Share Acquisition Offer from Biogen | SAGE Stock News
Biogen proposes to acquire all remaining Sage Therapeutics shares in unsolicited bid. Board of Directors to evaluate offer with independent advisors; no action required from shareholders.
Read more
2024-10-14 (theenterprise.news)
Biogen and Shareholders Seek Appellate Review in Class-Action Lawsuit
In a rare move, both Biogen and its shareholders have filed petitions with the 1st U.S. Circuit Court of Appeals, requesting a mid-case review of a trial court'
Read more
2024-07-18 (globenewswire.com)
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biogen To Contact Him Directly To Discuss Their Options If...
Read more
2024-06-29 (wrbl.com)
The Schall Law Firm Appeals To Biogen Inc Investors Who Have Experienced Losses To Connect Be Alert To The Time Limit In This Matter
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc.( `` Biogen '' or `` the Company '')( NASDAQ: BIIB) for violations of 10( b) and 20( a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
Read more
2024-06-26 (aktiencheck.de)
Biogen shares: Investors beware! ()
Biogen shares: Investors beware! () | aktiencheck.de
Read more
2024-06-24 (globenewswire.com)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
NEW YORK, June 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...
Read more
2024-06-20 (pr-inside.com)
Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class ...
Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class ...
Read more
2024-06-02 (pr-inside.com)
Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before ...
Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before ...
Read more
2024-05-25 (globenewswire.com)
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects ...
Read more
2023-11-17 (finanznachrichten.de)
Biogen at the annual meeting of the Society for Pediatric Neurology: Progress in rare diseases such as spinal muscular atrophy and Friedreich's ataxia
Dortmund (ots) - Biogen Germany, a leading provider of innovative therapies for neuromuscular and rare diseases, will be at GNP, the society's 48th annual meeting, from November 16th to 18th
Read more